Trial intelligence / Profile preview

International multicentre efficacy and safety study of I10E in CIDP after PRISM

2013-005558-31Phase 3Terminated

Sponsor
LFB Group
Start
Nov 2014
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, single-arm trial of subcuvia in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by LFB Group. Primary endpoint: Responder rate at end of study. Started Nov 2014; status: terminated.

02

Drugs

subcuvia
03

Conditions

chronic inflammatory demyelinating polyneuropathy (CIDP)

Beyond the preview

Go deeper on 2013-005558-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-005558-31.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call